{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-108413","form_type":"8-K","ticker":"PRLD","cik":"0001678660","company_name":"Prelude Therapeutics Inc","filed_at":"2025-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.617598+00:00","generated_at":"2026-05-17T13:15:28.141036+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Prelude Therapeutics Q2 net loss $31.2M; pauses IV SMARCA2 degrader, focuses on oral PRT7732","bullets":["Net loss of $31.2M ($0.41 per share) improved from $34.7M ($0.46) in Q2 2024.","Cash, equivalents and marketable securities $77.3M; runway into Q2 2026.","PRT3789 (IV) Phase 1 completed; will only advance with partnership. Oral PRT7732 enrolling 7th cohort (125 mg once daily); initial data by year-end 2025.","KAT6A degrader development candidate selected; IND on track for H1 2026.","R&D expense $25.8M (down from $29.5M); G&A $6.4M (down from $7.7M) YoY."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-108413","json":"https://secwatch.observer/filing/0000950170-25-108413.json","markdown":"https://secwatch.observer/filing/0000950170-25-108413.md","text":"https://secwatch.observer/filing/0000950170-25-108413.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1678660/000095017025108413/0000950170-25-108413-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1678660/000095017025108413/prld-20250814.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:15:28.141036+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}